Company intelligence / Profile preview

IrGen Pharma

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

IrGen Pharma is a clinical-stage biotechnology company dedicated to discovering and developing novel small molecule drugs that modulate the cGAS-STING pathway. The company focuses on treating autoimmune diseases, inflammatory disorders, and cancer by targeting innate immune signaling mechanisms. Its lead candidate, IRG-101, is a first-in-class cGAS inhibitor designed to treat interferon-mediated autoimmune diseases such as Aicardi-Goutières syndrome and systemic lupus erythematosus. Headquartered in Suzhou, China, IrGen Pharma utilizes its proprietary drug discovery platform to advance a pipeline of high-potency immunomodulators.

Therapeutic areas: OncologyImmunologyRheumatologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on IrGen Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IrGen Pharma.

Explore the full profile